Human tumor necrosis factor TR21 and methods based thereon

Details Human tumor necrosis factor TR21 and methods based thereon Human tumor necrosis factor TR21 and methods based thereon

2006-09-26

2006-09-26

O'Hara, Eileen B. (Department: 1646)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C530S350000, C530S351000, C536S023500, C536S023400

Reexamination Certificate

active

07112410

ABSTRACT:
The present invention relates to TR21 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR21 protein. TR21 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 activity. The invention further relates to the treatment, diagnosis, or prognosis of autoimmune diseases or disorders including Sjogren's syndrome using TR21 polynucleotides, polypeptides, agonists or antagonists.

REFERENCES:
patent: 2002/0115112 (2002-08-01), Yu et al.
patent: 2003/0059937 (2003-03-01), Ruben et al.
patent: 2004/0072188 (2004-04-01), Ambrose et al.
patent: WO-02/024909 (2002-03-01), None
patent: WO-02/028999 (2002-04-01), None
patent: WO-02/038766 (2002-05-01), None
patent: WO-02/092620 (2002-11-01), None
patent: WO-02/094852 (2002-11-01), None
patent: WO-03/014294 (2003-02-01), None
patent: WO-03/024991 (2003-03-01), None
patent: WO-03/031464 (2003-04-01), None
patent: WO-03/035846 (2003-05-01), None
patent: WO-03/045422 (2003-06-01), None
patent: WO-03/050134 (2003-06-01), None
patent: WO-03/055509 (2003-07-01), None
patent: WO-04/011611 (2004-02-01), None
U.S. Appl. No. 60/233,152, filed Sep. 18, 2000, Copy Not Readily Available.
Yan et al. Two-Amino Acid Molecular Switch in an Epithelial Morphogen That Regulates Binding to Two Distinct Receptors. Science, Vo. 290, Oct. 20, 2000, pp. 523-527.
Wells, 1990, Biochemistry, vol. 29, pp. 8509-8517.
GenBank Accession No. AI250289, NCI-CGAP, “qx03d08.x1 NCI—CGAP—Lym12Homo sapienscDNA clone IMAGE:2000271 3′, mRNA sequence” (Dec. 21, 1998).
GenBank Accession No. AW236483, NCI-CGAP, “xm46g10.x1 NCI—CGAP—GC6Homo sapienscDNA clone IMAGE:2687298 3′, mRNA sequence” (Dec. 13, 1999).
Thompson et al., “BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF”,Science 293(5537):2012-2013 (Sep. 14, 2001).
Yan et al., “Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency”,Curr. Biol. 11(19):1547-1552 (Oct. 2, 2001).
Ambrose, C.M., “BAFF-R”,J. Biol. Regul. Homeost. Agents16(3):211-213 (Jul.-Sep. 2002).

Affiliated with

Also associated with

Rating

Human tumor necrosis factor TR21 and methods based thereon does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human tumor necrosis factor TR21 and methods based thereon, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human tumor necrosis factor TR21 and methods based thereon will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3540180